Stock market recommendations: Pearl Global, and Indegene – these are the top stocks you can consider buying for the week starting September 28, 2026, as recommended by Motilal Oswal Wealth Management Research Desk. Below are the details:
| NAME | CMP (Rs) | TP (Rs) | Upside (%) |
| Pearl Global | 1318 | 1500 | 14% |
| Indegene | 608 | 708 | 16% |
Pearl GlobalPGIL is scaling its manufacturing capacity to support the next leg of growth, with capacity planned to increase from ~108m pieces to 120–140m by FY28 & 170–175m by FY30, at ~80% utilization. Higher wallet share from existing customers, a broader product portfolio & expansion across key manufacturing geographies are additional growth drivers.PGIL plans a total of Rs 6.75-7.25b capex through FY30, of which Rs 3.25-3.50b is earmarked for capacity expansion and Rs 3.5-3.75b for investments in knitting and dyeing. Knits are targeted to increase from ~26% to ~35% of capacity, while washing outsourcing is expected to decline from ~60% to 20-25%, supporting margin expansion.We estimate revenue/EBITDA/PAT CAGR of 17%/32%/38% over FY26-FY28, with EBITDA margins expected to expand to 12–14% and RoCE to 22–25%. Management targets Rs 90–100b revenue by FY30, implying 16–18% growth from FY26, with capacity additions, product diversification & higher wallet share driving the outlook.IndegeneIndegene is well positioned to benefit from rising pharma outsourcing, as expanding drug pipelines, clinical complexity and regulatory pressures drive life sciences companies to focus internal resources on core R&D. Its integrated platform spans clinical, regulatory, medical and commercial operations, covering the commercialization lifecycle from evidence generation to lifecycle optimization, supported by a common data, analytics and technology backbone.Operationally, Indegene remains in the top quartile, given superior revenue per employee. We estimate a CAGR of ~19%/29%/27% in revenue/EBIT/PAT over FY26-28. EBITDA margin is set to recover to 19-20% by 4QFY27, aided by operating leverage. We upgrade our rating to BUY.(Disclaimer: Recommendations and views on the stock market, or any other asset classes or personal finance management tips given by experts and analysts are their own. These opinions do not represent the views of The Times of India.)
